Down-Regulated Expression of Cytokeratin 18 Promotes Progression of Human Breast Cancer

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2670-2674

  Woelfle, Ute ^a   Sauter, Guido ^b   Santjer, Sonja ^a   Brakenhoff, Ruud ^c   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

AGED; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1942470138     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0114     Document Type: Article

References (35)

1. Hesse M, Magin TM, Weber K. Genes for intermediate filament proteins and the draft sequence of the human genome: novel keratin genes and a surprisingly high number of pseudogenes related to keratin genes 8 and 18. J Cell Sci 2001;114:2569-75.
2. Coulombe PA, Hutton ME, Letai A, et al. Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. Cell 1991;66:1301-11.
3. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science (Wash DC) 1998;279:514-9.
4. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors, and cultured cells. Cell 1982;31:11-24.
5. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst (Bethesda) 1999;91:1113-24.
6. Coulombe PA, Omary MB. "Hard" and "soft" principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002;14:110-22.
7. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-29.
8. Blouin R, Swierenga SH, Marceau N. Evidence for post-transcriptional regulation of cytokeratin gene expression in a rat liver epithelial cell line. Biochem Cell Biol 1992;70:1-9.
9. Knapp AC, Franke WW. Spontaneous losses of control of cytokeratin gene expression in transformed, non-epithelial human cells occurring at different levels of regulation. Cell 1989;59:67-79.
10. Choi I, Gudas LJ, Katzenellenbogen BS. Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. Mol Cell Endocrinol 2000;164:225-37.
11. Hesse M, Franz T, Tamai Y, Taketo MM, Magin TM. Targeted deletion of keratins 18 and 19 leads to trophoblast fragility and early embryonic lethality. EMBO J 2000;19:5060-70.
12. Zajchowski DA, Bartholdi MF, Gong Y, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001;61:5168-78.
13. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
14. Woelfle U, Cloos J, Sauter G, et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 2003;63:5679-84.
15. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188-94.
16. Schlimok G, Funke I, Holzmann B, et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987;84:8672-6.
17. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347:649-53.
18. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
19. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (Oxf) 1991;19:403-10.
20. Pantel K, Schlimok G, Angstwurm M, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:165-73.
21. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
22. Klein CA, Blankenstein TJF, Schmidt-Kittler O, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
23. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
24. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999;154:981-6.
25. Barlund M, Forozan F, Kononen J, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst (Bethesda) 2000;92:1252-9.
26. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
27. Solakoglu O, Maierhofer C, Lahr G, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 2002;99:2246-51.
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
29. Schaller G, Fuchs I, Pritze W, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996;2:1879-85.
30. Petruzzelli GJ, Benefield J, Yong S. Mechanism of lymph node metastases: current concepts. Otolaryngol Clin N Am 1998;31:585-99.
31. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
32. Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratin 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;163:1991-6.
33. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990;136:219-27.
34. Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 1996;179:386-91.
35. Oshima RG, Abrams L, Kulesh D. Activation of an intron enhancer within the keratin 18 gene by expression of c-fos and c-jun in undifferentiated F9 embryonal carcinoma cells. Genes Dev 1990;4:835-48.